Adetola Kassim

From the 2026 National Summit on Hematologic Cancers

Supplementary Figure S7: Clinical variables associated with time to hematopoietic regeneration after allogeneic transplantation at Vanderbilt.

Supplementary Figure S9: The inhibitory effect of carvedilol on hematopoietic regeneration after syngeneic transplantation can be overcome by transplanting larger doses of bone marrow cells.

Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.

Supplementary Table S6. Related to Fig. 1-7. Key Resources Table.

Supplementary Figure S8: Hematopoietic stem and progenitor cell frequencies after allogeneic transplantation.

Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.

Supplementary Table S3. Characteristics of Vanderbilt autologous transplant patients. Continuous measures are shown as mean (SD), and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.

Carvedilol treatment impairs hematopoietic regeneration in mice after syngeneic and allogeneic BM transplants. Mice were treated with nonselective β-blocker, carvedilol, or vehicle control for 7 days before BM transplantation and 21 days after transplantation. Each panel shows data from four independent experiments, and each dot represents a different mouse. All data represent mean ± SD. A–L, 6 × 105 C57BL/Ka BM cells were syngeneically transplanted into irradiated C57BL/Ka-Thy-1.2 recipients. At 21 days after transplantation, we analyzed WBC (A), RBC (B), and PLT (C) counts; BM (D) and spleen (E) cellularity; and the frequencies of HSCs, MPPs, and LSK cells in the BM (F–H) and spleen (I–K) of carvedilol-treated (red, n = 19) and vehicle-treated (black, n = 17) mice. L, Survival of carvedilol-treated (red, n = 44) and vehicle-treated (black, n = 18) mice over time after syngeneic transplantation. M–X, 6 × 105 T cell–depleted LP/J BM cells were allogeneically transplanted into irradiated C57BL/Ka-Thy-1.2 recipients. At 21 days after transplantation, we analyzed WBC (M), RBC (N), and PLT (O) counts, as well as BM (P) and spleen (Q) cellularity and the frequencies of HSCs, MPPs, and LSK cells in the BM (R–T) and spleen (U–W) of carvedilol-treated (red, n = 17) and vehicle-treated (black, n = 18) mice. X, Survival of carvedilol-treated (red, n = 44) and vehicle-treated (black, n = 20) mice over time after allogeneic transplantation. Y and Z, The number of CD41+ megakaryocytes (Y) or Gr1+ myeloid cells (Z) per field of view was counted in BM sections from carvedilol-treated (red, n = 10) and vehicle-treated (black, n = 10) mice at 13 days after transplantation. The statistical significance of differences among treatments were assessed using the Student t tests followed by Holm–Sidak multiple comparisons adjustments (A–C and M–T), matched samples two-way ANOVAs followed by Holm–Sidak multiple comparisons adjustments (D, E, I–K, Y, and Z), Student or Welch’s t tests followed by Holm–Sidak multiple comparisons adjustments (F–H), Mann–Whitney tests followed by Holm–Sidak multiple comparisons adjustments (U–W), or log-rank Mantel–Cox tests (L and X). All statistical tests were two sided.